Carl Spalding Joins PharmaNet Development Group Board of Directors

PRINCETON, N.J., March 8 /PRNewswire/ --  PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Carl Spalding has joined the Company's Board of Directors.

"We are very pleased to have Carl join our Board," commented Jeffrey P. McMullen, President and Chief Executive Officer. "His depth of experience with clinical development, from the perspective of both a contract research organization and pharmaceutical company, will be a valuable asset to the shared vision and guidance of our Board of Directors."

Mr. Spalding is past President and Chief Operating Officer of PAREXEL, a publicly-traded, global contract research organization. Prior to joining PAREXEL, Mr. Spalding held senior positions at major healthcare companies, including Cardinal Health, Abbott, and Johnson & Johnson.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  

    
    
    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: [email protected]

SOURCE PharmaNet Development Group, Inc.